Phosphazide: a new drug in the antiretroviral portfolio of Promomed Group

Promomed Group received marketing authorization certificate for Phosphazide, a drug product used in combination therapy for HIV infection and in emergency prevention of occupational HIV infection. It became the sixth approved drug product in the company's antiretroviral portfolio.

Phosphazide suppresses activity of HIV-1 and HIV-2 reverse transcriptase due to inclusion in the viral DNA resulting in breaking the chain and stopping the reproduction of viral particles. It also suppresses replication of other retroviruses, therefore it can be used for the treatment of acute hepatitis B in mild or moderate form.

The development and production of drug products aimed at the treatment of major critical diseases, including the human immunodeficiency virus, is one of the most important strategic areas for Promomed Group, a company focused on solving topical medical problems, saving and significantly improving patients’ quality of life. Phosphazide will be produced at Biokhimik JSC in the full production cycle: from the substance to the finished form.

The drug will be available in the form of 200 and 400 mg tablets, which corresponds to standard intake regimens.

Like most drug products produced by Promomed Group, Phosphazide is included in the list of VED.